ML_LMIC: Testing a Precision Psychotherapy System for Low-income Patients

Sponsor
National Council of Scientific and Technical Research, Argentina (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05118594
Collaborator
(none)
111
1
9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the feasibility of an evidence-based system to recommend core interventions, before the beginning of treatment, to psychotherapists treating low-income patients with depressive or anxiety disorders.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Pre-treatment psychotherapy recommendations
N/A

Detailed Description

After providing a written inform consent, potential patients will undergo a 2-weeks screening period to determine if they meet eligibility criteria. Baseline information (i.e., derived from semi-structured intake interviews and baseline clinical measures) from patients who meet eligibility criteria and consent to participate in the study, will be use to feed a machine learning algorithm, developed in a previous study, to perform individual predictions and determine which interventions (i.e., cognitive, behavioral, interpersonal, or patient-centered) will be recommended for the individual patient. This recommendation (i.e., about the most personally well-suited intervention for a given patient) will be provided to therapists before the beginning of treatment. Patients will be treated with 15 sessions of psychotherapy. The investigators will examine the extent to which therapists adhered to the recommended interventions as the primary outcome. The investigators will also examine patient symptomatic/functional improvement as a secondary outcome.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
111 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Therapists will receive patient-specific treatment recommendations (based on a machine-learning based algorithm developed in a previous study) regarding the most suitable interventions to be used to treat each study patient.Therapists will receive patient-specific treatment recommendations (based on a machine-learning based algorithm developed in a previous study) regarding the most suitable interventions to be used to treat each study patient.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Open-trial to Prospectively Test the Feasibility of a Precision Psychotherapy System for Low-income Patients
Anticipated Study Start Date :
Feb 1, 2026
Anticipated Primary Completion Date :
Nov 1, 2026
Anticipated Study Completion Date :
Nov 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pre-treatment recommendations

Therapists receive automatized feedback at the beginning of the treatments with recommendations regarding the most appropriate interventions to use with their patients based on a machine learning algorithm developed on a previous study.

Behavioral: Pre-treatment psychotherapy recommendations
After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.

Outcome Measures

Primary Outcome Measures

  1. Change from Baseline in Depressive Severity on the Patient Health Questionnaire (PHQ-9) at Week 15 [Baseline and Week 15]

    The PHQ-9 is a validated 9-item self-reported measure of depression severity grounded on the diagnostic criteria from the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV), with higher scores representing greater severity. Items are rated on a four-point Likert scale ranging from 0 ("Not at all") to 3 ("Nearly every day"). Change= Estimated weekly change from Baseline to Week 15 from a multilevel growth curve model

  2. Change from Baseline in Anxiety Severity on the General Anxiety Disorder-7 (GAD-7) at Week 15 [Baseline and Week 15]

    The GAD-7 is a self-reported measure that evaluates the overall anxiety severity with seven items rated on a four-point Likert scale ranging from 0 ("Not at all) to 3 ("Nearly every day"). Greater scores represents higher severity. Change= Estimated weekly change on severity from Baseline to Week 15 from a multilevel growth curve model

  3. Change from Baseline in Overall Functioning on the World Health Organization Disability Assessment Schedule (WHODAS) at Week 15 [Baseline and Week 15]

    The WHODAS is a validated self-reported measure that evaluates overall functioning with 12 items rated on a five-point Likert scale ranging from 0 ("None") to 4 ("Extreme"). Greater scores represents higher disability. Change= Estimated weekly change on severity from Baseline to Week 15 from a multilevel growth curve model

  4. Average Adherence to the Recommended Interventions on the Multitheoretical List of Therapeutic Interventions (MULTI-30) Across Treatment [Week 1 and Week 15]

    The MULTI-30 is a validated and reliable measure to assessed the adherence to therapeutic interventions in a given session. Items are rated on a 5-point Likert scale ranging from 1 ("Not at all typical to the session") to 5 ("Very typical to the session"). For the project the investigators will test the following MULTI-30 subscales: Cognitive, Behavioral, Interpersonal, and Person-centered. In this study the investigators will use the therapist version of the MULTI-30. Average Adherence= Mean Score of the Recommended Interventions Across all the Sessions of the Treatment.

Secondary Outcome Measures

  1. Diagnostic Status at Week 15 in the Primary Diagnoses Identified at Baseline with the Mini-International Neuropsychiatric Interview [Baseline and Week 15]

    The MINI is a brief structured diagnostic interview for psychiatric disorders developed based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD) diagnostic criteria. Several studies have positioned the MINI as a highly reliable and valid instrument for determine psychiatric disorders. Diagnostic Status= Determine if the primary diagnoses remain at Week 15

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnoses of a depressive disorder (i.e., major depressive disorder or dysthymic disorder) or an anxiety disorder (i.e., specific phobia, social anxiety disorder, panic disorder, agoraphobia or generalized anxiety disorder) determined with the Mini-International Neuropsychiatric Interview (MINI)

  • A score of at least two (mild) in any the five items from the depression and anxiety domains of the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure-Adult

  • A total family income below the poverty index threshold, determined by a Licensed Social Worker

  • Aged 18 to 65

  • Fluency in Spanish language

  • Capacity to consent

Exclusion Criteria:
  • Psychosis

  • Mania

  • Suicidal ideation with intent and/or plan

  • Substance abuse disorders

  • History of organic mental disease.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • National Council of Scientific and Technical Research, Argentina

Investigators

  • Principal Investigator: Juan M Gomez Penedo, PhD, National Council of Scientific and Technical Research

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Juan Martin Gomez Penedo, Assistant Researcher, National Council of Scientific and Technical Research, Argentina
ClinicalTrials.gov Identifier:
NCT05118594
Other Study ID Numbers:
  • ML_LMIC_2021
First Posted:
Nov 12, 2021
Last Update Posted:
Nov 18, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Juan Martin Gomez Penedo, Assistant Researcher, National Council of Scientific and Technical Research, Argentina
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2021